

# **Paediatric Clinical Trial Site Standards**

## **Work Group 1**

**Defining what quality of paediatric sites means**

## **Enpr-EMA Annual meeting**

Ricardo Fernandes (STAND4Kids; c4c) & Solange Corriol-Rohou (AZ)  
Co-Chairs WG1

10 October 2023

# Background Information

- **On Oct. 3, 2022:** Workshop on paediatric site quality requirements co-organised by Enpr-EMA and conect4children (c4c) → Identified Action Points
  - Definition of quality of paediatric trial sites: how can conduct be optimised, what matters to different stakeholders, including children, young people and their families
  - Identification/mapping of existing quality standards
  - Implementation of the recommendations for quality criteria/standards: Roadmap – how to? Publication of a recommendation document.
- **On Jan. 26, 2023:** Follow Up Meeting → Discussion Points
  - Groups aiming to define and identify quality standards for paediatric clinical trials could start their work in parallel, at a later stage merge, and work together in the implementation phase.
  - After the definition/identification of general criteria, specificities for specific cases could be defined.
  - Considerations were given to de-centralised clinical trial elements, innovation and digitalisation
  - Need to avoid duplication of work of other ongoing initiatives
- **Two Enpr-EMA Work Groups formed**
  - WG 1: Defining what quality of paediatric sites means
  - WG 2: Identifying/mapping existing quality criteria/standards for sites

# WG1 Members

<i>Name</i>	<i>Affiliation</i>
<b>Arianna Bertolani</b>	CVBF
<b>Begonya Nafria Escalera</b>	eYPAGnet
<b>Breanne Stewart</b>	MICYRN
<b>Carmen Rodríguez-Tenreiro</b>	GENVIP
<b>Collin Hovinga</b>	Critical-Path Institute
<b>Ensio Norjavaara</b>	AstraZeneca
<b>Eva Degraeuwe</b>	c4c, BPCRN
<b>Fernando Cabanas</b>	Red Samid, PDCO
<b>Holly Huntington</b>	I-ACT
<b>Ivan Foeldvari</b>	JSWG of PRES - Juvenile Scleroderma Working Group
<b>Jorge Alonso</b>	JNJ
<b>Laura Persijn</b>	C4c, BPCRN
<b>Lionel Tan</b>	Viiv Healthcare
<b>Martine Dehlinger-Kremer</b>	ICON plc (CRO)
<b>Mark Sorrentino</b>	ICON plc (CRO)
<b>Melissa Walsh</b>	c4c, IN4KIDS
<b>Nicola Ruperto</b>	PRINTO
<b>Pavla Pokorna</b>	C4c, Czech PharmNet
<b>Sabrina Pierre</b>	c4c; INSERM
<b>Sarah Zaidi</b>	FDA
<b>Tessa van der Geest</b>	Pedmed-NL
<b>Thierry Lacaze</b>	MICYRN

# WG1 Objectives – Defining what does Quality of Paediatric Site mean

- Aims and scope
  - To develop a common understanding of what quality of paediatric sites means with regards to paediatric clinical trial sites and what matters to the different stakeholders involved in the conduct of a clinical trial, including children and their parents/ caregivers.
  - This work addresses paediatric site standards across jurisdictions, paediatric age ranges, and types of sponsor; inclusive to a diversity of types of sites and site involvement; and is focused on sites delivering regulatory-grade clinical trials.
  - The work intends to drive opportunities for rollout of site standards and improvement of sites, with adequate resources.

# WG1 Methods – Defining what does Quality of Paediatric Site mean

- Ways of working
  - Five remote meetings with open discussions, moderated by Chairs
  - Main discussion points, topics with agreement and dissent, and distinct perspectives from various stakeholders were captured
  - Offline work helped focus on specific questions, identify and share supporting evidence (environmental scan)
- Liaised with WG2 for shared alignment, synergy and efficiency
- Interim report on our groups' operational approach, plan and first ideas at the (virtual) Enpr-EMA Coordinating Group meeting in June

# What has WG1 delivered?

- A document focusing on 4 questions:
  - What is a paediatric site?
  - Why do we need paediatric site standards?
  - What do we mean by quality of a paediatric site?
  - How to identify a fit-for-purpose paediatric site?
- Align with WG2 → joint document with recommendations

# Next steps and future directions – for discussion

- To incorporate further input and finalise our WG1 recommendations
- To consolidate with WG2 identified standards and other sources of information
- To plan dissemination and implementation steps, aligned with existing initiatives and target stakeholders